Alexion Reports Results of Ultomiris (ravulizumab-cwvz) in P-III Study in Patients with Atypical Hemolytic Uremic Syndrome (AHUS)
Shots:
- The P-III study involves assessing of Ultomiris (IV) in complement inhibitor-naïve patients with aHUS- receiving dose based on their weight varying upto 3-600 mg for 2 years
- P-III study results: reduction in thrombocytopenia in 83.9% patients; reduction in hemolysis in 76.8% patients; improved kidney function in 58.9% patients; No case of meningococcal infection observed; safe results
- Ultomiris (ravulizumab-cwvz) is a mAb and has received ODD from the US and EU for Paroxysmal Nocturnal Hemoglobinuria (PNH) in adults and aHUS in SC respectively
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
